Why are Lipid Formulations Commonly Used to Enhance Bioavailability?

Enabling formulations becomes more and more necessary to obtain adequate exposure of APIs during (pre)-clinical research. Currently, most registered formulations to improve bioavailability are based on lipidic systems, which make use of intrinsic digestion processes within the GI tract, facilitating the absorption of APIs. Aside from a general absorption mechanism, lipidic systems can also promote lymphatic transport of poorly soluble drugs, such as hormones. In addition, many different indications, such as HIV therapy, oncology, immunosuppressant and even arising therapies related to medicinal cannabis (e.g. CBD) can benefit from lipid formulations. These formulations create multiple possibilities for oral administration because they can be manufactured as solutions, suspensions, emulsions, and self-(micro)emulsifying systems.
Watch Now

Spotlight

OTHER ON-DEMAND WEBINARS

Exploring MALDI-TOF mass spec for mycobacteria

captodayonline

The Food and Drug Administration in 2017 approved MALDI-TOF mass spectrometry for the identification of mycobacteria. What is the protocol? How is workflow affected? Are there cost savings and turnaround time improvements? Omai Garner, PhD, D(ABMM), answered these and other questions and shared his laboratory’s validation data in a Dec. 13, 2018 CAP TODAY webinar supported by Bio¬Mérieux (captodayonline.com). Here is an edited transcript of what he said.
Watch Now

Tau Biology and Pathology in and Beyond Alzheimer’s Disease

Abcam plc

Watch this on-demand webinar presented by Dr. Akihiko Takashima and Dr. Ioannis (John) Sotiropoulos and learn about the emerging views on the role and function of Tau in neurons - including its recently suggested contributions to scaffolding and signaling.
Watch Now

Strategic Considerations for Scaling Up the Manufacturing of Cell Therapies

Amid a growing number of cell therapies reaching late-stage clinical studies and commercial launch, the considerations required to deliver scalable commercial manufacturing, including meeting reduced timelines and the increased demand for capacity, are critical to getting these cell products to patients.
Watch Now

Pharmaron’s cell and gene therapy webinar series

Pharmaron has taken their platform beyond small molecules and are pleased to now offer a full array of services for biologics and cell and gene therapies (CGTs). Our new CGT webinar series focusses on identifying key cell and gene therapy questions that arise during drug discovery and development.
Watch Now

Spotlight

resources